Cinctive Capital Management LP Has $1.41 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Cinctive Capital Management LP boosted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 111.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,094 shares of the company’s stock after buying an additional 16,883 shares during the period. Cinctive Capital Management LP’s holdings in Structure Therapeutics were worth $1,409,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of GPCR. Teachers Retirement System of The State of Kentucky grew its position in Structure Therapeutics by 17.8% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock valued at $589,000 after purchasing an additional 2,077 shares in the last quarter. Mather Group LLC. acquired a new stake in Structure Therapeutics during the second quarter valued at $214,000. Principal Financial Group Inc. purchased a new position in Structure Therapeutics in the second quarter valued at about $6,489,000. Natixis Advisors LLC increased its position in Structure Therapeutics by 29.4% in the 2nd quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock worth $746,000 after purchasing an additional 4,321 shares during the last quarter. Finally, Gilbert & Cook Inc. purchased a new stake in shares of Structure Therapeutics during the 2nd quarter worth about $229,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Trading Down 2.0 %

NASDAQ GPCR opened at $33.25 on Wednesday. Structure Therapeutics Inc. has a 1 year low of $26.61 and a 1 year high of $66.38. The company has a fifty day simple moving average of $37.83 and a 200 day simple moving average of $39.42. The company has a market cap of $1.90 billion, a P/E ratio of -44.93 and a beta of -3.41.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities lowered their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $86.80.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.